| Literature DB >> 30401435 |
Ara Koh1, Antonio Molinaro1, Marcus Ståhlman1, Muhammad Tanweer Khan1, Caroline Schmidt2, Louise Mannerås-Holm1, Hao Wu1, Alba Carreras1, Heeyoon Jeong3, Louise E Olofsson1, Per-Olof Bergh1, Victor Gerdes4, Annick Hartstra5, Maurits de Brauw4, Rosie Perkins1, Max Nieuwdorp6, Göran Bergström2, Fredrik Bäckhed7.
Abstract
Interactions between the gut microbiota, diet, and the host potentially contribute to the development of metabolic diseases. Here, we identify imidazole propionate as a microbially produced histidine-derived metabolite that is present at higher concentrations in subjects with versus without type 2 diabetes. We show that imidazole propionate is produced from histidine in a gut simulator at higher concentrations when using fecal microbiota from subjects with versus without type 2 diabetes and that it impairs glucose tolerance when administered to mice. We further show that imidazole propionate impairs insulin signaling at the level of insulin receptor substrate through the activation of p38γ MAPK, which promotes p62 phosphorylation and, subsequently, activation of mechanistic target of rapamycin complex 1 (mTORC1). We also demonstrate increased activation of p62 and mTORC1 in liver from subjects with type 2 diabetes. Our findings indicate that the microbial metabolite imidazole propionate may contribute to the pathogenesis of type 2 diabetes.Entities:
Keywords: IRS; histidine; imidazole propionate; mTORC1; microbiome; p38γ; p62
Mesh:
Substances:
Year: 2018 PMID: 30401435 DOI: 10.1016/j.cell.2018.09.055
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582